Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

Biometrical Journal, EarlyView.

Source: Biometrical Journal - May 29, 2018 Category: Biotechnology Authors: Jose L.Jimenez , MouradTighiouart , MauroGasparini Source Type: research